

**Decision Point: GF/B40/EDP12: Decision on the Secretariat’s Recommendation on Funding from the 2017-2019 Allocation**

The Board:

1. Approves the funding recommended for each country disease component, and its constituent grants, as listed in the Tables 1a and 1b of GF/B40/ERO9 (“Table 1a” and “Table 1b”);
2. Acknowledges each country disease component’s constituent grants will be implemented by the proposed Principal Recipients listed in Table 1a, or any other Principal Recipient(s) deemed appropriate by the Secretariat in accordance with Global Fund policies;
3. Affirms the funding approved under this decision (a) is subject to the availability of funding, and (b) shall be committed in annual tranches; and
4. Delegates to the Secretariat authority to redistribute the overall upper-ceiling of funding available for each country disease component among its constituent grants, provided that the Technical Review Panel (the “TRP”) validates any redistribution that constitutes a material change from the program and funding request initially reviewed and recommended by the TRP.

**Table 1a: Secretariat’s Recommendation on Funding from the 2017-2019 Allocation** - Please note that each country name is linked to the extranet site where supporting documents are available for review

N	Applicant	Disease Component	Grant Name <sup>3</sup>	Grant End Date	Currency	Total Program Budget	Catalytic Funds in Grant	Domestic Commitment <sup>4</sup>	Unfunded Quality Demand
1	Benin	RSSH	BEN-S-CNLS-TP	30-06-2022	EUR	12,191,862	2,138,640	N/A	5,223,203
2	Chad	HIV	TCD-H-MOH	31-12-2021	EUR	34,486,906	N/A	15,930,796	6,269,599
3		TB	TCD-T-MOH			4,291,907			
4	Nigeria	HIV	NGA-H-NACA	31-12-2020	USD	5,893,310	N/A	61,756,987	40,831,337
5		HIV	NGA-H-SFHNG	31-12-2020	USD	15,894,545	N/A	61,756,987	40,831,337
6		HIV	NGA-H-FHI360	31-12-2020	USD	87,666,232	N/A	61,756,987	40,831,337
7		TB/HIV/RSSH	NGA-C-LSMOH	31-12-2020	USD	15,931,763 <sup>5</sup>	N/A	N/A	6,072,398

8		RSSH	NGA-S-MSH	31-12-2020	USD	42,996,203	N/A	N/A	6,072,398
9	Multicountry IGAD	TB	QPA-T-IGAD	31-03-2022	USD	7,500,000	7,500,000	N/A	-
10	South Africa	TB/HIV	ZAF-C-AFSA	31-03-2022	USD	59,762,556	16,000,000	7,456,708,765	189,031,883

11			ZAF-C-BZ			53,783,128			
12			ZAF-C-NACOSA			82,059,426			
13			ZAF-C-NDOH			173,716,011			

**Table 1b: Secretariat's Recommendation on Integrating Matching Funds into Board Approved Grants from the 2017-2019 Allocation** - Please note that each country name is linked to the extranet site where supporting documents are available for review

N	Applicant	Disease Component	Grant Name	Additional Funding Source	Currency	Previously Approved Program Budget	Recommended Additional Funding	Revised Program Budget
1	Senegal	HIV	SEN-H-CNLS	Catalytic Funds (Matching funds)	EUR	15,739,822	1,056,549	16,796,371
2			SEN-H-ANCS			6,128,471	1,014,434	7,142,905
3	Guinea	Malaria	GIN-M-CRS	Catalytic Funds (Matching funds)	USD	55,663,302	3,000,000	58,663,302

<sup>3</sup> The Grant names are subject to change based on the ISO code.

<sup>4</sup> Domestic commitments pertain to the disease programs and exclude other specific commitments for RSSH, unless otherwise specified. Commitments for disease specific programs and RSSH are subject to local currency value fluctuation against US dollar and Euro currencies.

<sup>5</sup> Total composition: US\$5,089,851 for TB (already approved by the Board through GF/B40/EDPo2), US\$8,468,527 for HIV and US\$2,373,385 for RSSH. Therefore, Board approval is sought for US\$10,841,912 for HIV and RSSH.